Medicines and Healthcare products Regulatory Agency

MANUFACTURER'S AUTHORISATION

1: Authorisation Number UK MIA(IMP) 48152

2: Name of authorisation holder CELL AND GENE THERAPY CATAPULT

CELL AND GENE THERAPY CATAPULT MANUFACTURING AND

INNOVATION CENTRE, 4 WARNER DRIVE, SPRINGWOOD

INDUSTRIAL ESTATE, BRAINTREE, CM7 2YW, UNITED KINGDOM

CELL AND GENE THERAPY CATAPULT, 12TH FLOOR TOWER WING,

4: Legally registered address of authorisation holder GUY'S HOSPITAL, GREAT MAZE POND, LONDON, SE1 9RT, UNITED

KINGDOM

5: Scope of authorisation and dosage forms ANNEX 1 and/ or ANNEX 2

6: Legal Basis of authorisation

Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004

[SI 2004/1031]

7: Name of responsible officer of the competent

authority of the member state granting the

3: Address(es) of manufacturing site(s)

manufacturing authorisation

Confidential

8: Authorisation Date 02/02/2024

9: Annexes attached Annex 1 and/or Annex 2

SCOPE OF AUTHORISATION

Annex 2

Name and address of the site:

CELL AND GENE THERAPY CATAPULT MANUFACTURING AND INNOVATION CENTRE, 4 WARNER DRIVE, SPRINGWOOD INDUSTRIAL ESTATE, BRAINTREE, CM7 2YW, UNITED KINGDOM

Human Investigational Medicinal Products

Authorised Operations

MANUFACTURING OPERATIONS (according to part 1)

Part 1 - MANUFACTURING OPERATIONS

[1.1] Sterile Investigational Medicinal Products

[1.1.1] Aseptically prepared (processing operations for the following dosage forms)

[1.1.1.1] Large volume liquids

Special Requirements

Live Cells

Advanced Therapy Medicinal Products

Issue Date: 02 Feb 2024

[1.1.1.4] Small volume liquids

Special Requirements

Live Cells

Advanced Therapy Medicinal Products

[1.1.1.6] Other aseptically prepared products

Cell and viral vector based Advanced Therapeutic Medicinal Products

Special Requirements

Live Cells

Advanced Therapy Medicinal Products

[1.1.3] Batch certification

[1.3] Biological investigational medicinal products

[1.3.1] Biological medicinal products

[1.3.1.3] Cell therapy products

Special Requirements

Live Cells

Advanced Therapy Medicinal Products

[1.3.1.4] Gene therapy products

Special Requirements

Live Cells

Advanced Therapy Medicinal Products

[1.3.1.5] Biotechnology products

Special Requirements

Live Cells

Advanced Therapy Medicinal Products

[1.3.1.6] Human or animal extracted products

Special Requirements

Live Cells

Advanced Therapy Medicinal Products

[1.3.1.8] Other biological medicinal products

Viral vectors

Special Requirements

Live Cells

Advanced Therapy Medicinal Products

[1.3.2] Batch certification

[1.3.2.3] Cell therapy products

Special Requirements

Live Cells

Advanced Therapy Medicinal Products

[1.3.2.4] Gene therapy products

Special Requirements

Live Cells

Advanced Therapy Medicinal Products

[1.3.2.5] Biotechnology products

Special Requirements

Live Cells

Advanced Therapy Medicinal Products

Issue Date: 02 Feb 2024

[1.3.2.6] Human or animal extracted products

Special Requirements

Live Cells

Advanced Therapy Medicinal Products

[1.3.2.8] Other biological medicinal products

Viral vectors

Special Requirements

Live Cells

Advanced Therapy Medicinal Products

[1.4] Other investigational medicinal products or manufacturing activitiy

[1.4.2] Sterilisation of active substances/excipients/finished products:

[1.4.2.1] Filtration

[1.5] Packaging

[1.5.1] Primary packaging

[1.5.1.6] Liquids for internal use

[1.5.1.15] Other non-sterile medicinal products

Cell based Advanced Therapeutic Medicinal Products

[1.5.2] Secondary packaging

[1.6] Quality control testing

[1.6.1] Microbiological: sterility

[1.6.2] Microbiological: non-sterility

[1.6.3] Chemical/Physical

[1.6.4] Biological



Issue Date: 02 Feb 2024 Manufacturer's Authorisation: UK MIA(IMP) 48152